Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Robbins

Showing results (581-590 of 598) with videos related to

Pageof 60
Sort By:
Journal of the American College of Radiology : JACR|November 6, 2020
ACR Appropriateness Criteria® Postpartum Hemorrhage, Jennifer W Uyeda, Elizabeth George, et al.
Academic Radiology|August 11, 2020
USMLE Step 3 Scores Have Value in Predicting ABR Core Examination Outcome and Performance: A Multi-institutional StudyMaitray D Patel, Thad Benefield, Katie N Hunt, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
ESMO Open|April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trialT K Choueiri, J Larkin, S Pal, et al.
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update, Olga R Brook, Joseph R Dadour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 TrialMehmet A Bilen, Brian I Rini, Martin H Voss, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohortNeil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Science Translational Medicine|September 19, 2014
Broadly neutralizing antibodies abrogate established hepatitis C virus infectionYpe P de Jong, Marcus Dorner, Michiel C Mommersteeg, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Vaccine|December 17, 2008
International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007M L Tondella, G M Carlone, N Messonnier, et al.
Pageof 60

Showing results (581-590 of 598) with videos related to

Sort By:
Pageof 60
Journal of the American College of Radiology : JACR|November 6, 2020
ACR Appropriateness Criteria® Postpartum Hemorrhage, Jennifer W Uyeda, Elizabeth George, et al.
Academic Radiology|August 11, 2020
USMLE Step 3 Scores Have Value in Predicting ABR Core Examination Outcome and Performance: A Multi-institutional StudyMaitray D Patel, Thad Benefield, Katie N Hunt, et al.
The Lancet. Oncology|March 14, 2018
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trialToni K Choueiri, James Larkin, Mototsugu Oya, et al.
ESMO Open|April 26, 2021
Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trialT K Choueiri, J Larkin, S Pal, et al.
Journal of the American College of Radiology : JACR|June 1, 2024
ACR Appropriateness Criteria® Acute Pelvic Pain in the Reproductive Age Group: 2023 Update, Olga R Brook, Joseph R Dadour, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2021
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 TrialMehmet A Bilen, Brian I Rini, Martin H Voss, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2019
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohortNeil H Segal, Sai-Hong I Ou, Ani Balmanoukian, et al.
Science Translational Medicine|September 19, 2014
Broadly neutralizing antibodies abrogate established hepatitis C virus infectionYpe P de Jong, Marcus Dorner, Michiel C Mommersteeg, et al.
Cancer Immunology Research|April 1, 2022
Hallmarks of Resistance to Immune-Checkpoint InhibitorsMaria Karasarides, Alexandria P Cogdill, Paul B Robbins, et al.
Vaccine|December 17, 2008
International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007M L Tondella, G M Carlone, N Messonnier, et al.
Pageof 60